Hybio Pharmaceutical Co., Ltd.: GLP-1 products listed with FDA

Every GLP-1 product Hybio Pharmaceutical Co., Ltd. lists

One row per product NDC, in FDA’s words. Strength is printed as FDA lists it, spacing tidied.

The rest of its federal record

Checked against every GLP-1 record we publish from FDA. A recall or shortage counts when FDA printed one of this firm’s NDCs in it; a letter or 503B entry counts when the firm name matches exactly. Similar names are listed apart and not counted.

What these listings mean, and what they do not

• Approved product. A finished product sold under an approved application (NDA, BLA or ANDA). The approval belongs to the application, which Drugs@FDA lists with its holder; the NDC is only the product's identifier.
• Bulk ingredient. The active ingredient itself, as powder or solution, sold to manufacturers or, where the listing says so, to compounders. A listing tells FDA the firm makes or sells it; it is not an approval of the ingredient or of anything made from it.

“Inclusion in the NDC Directory does not indicate that FDA has verified the information provided or that the products are FDA-approved.”FDA, National Drug Code Directory page, confirmed on the page Oct 4, 2026. fda.gov ↗

“Assignment of an NDC number does not in any way denote FDA approval of the product.”FDA, National Drug Code Directory page, confirmed on the page Oct 4, 2026. fda.gov ↗

“A labeler may be a manufacturer, including a repackager or relabeler, or the entity named on the product label.”FDA, National Drug Code Directory page, confirmed on the page Oct 4, 2026. fda.gov ↗

“The content of each NDC Directory entry is the responsibility of the labeler submitting the SPL file.”FDA, National Drug Code Directory page, confirmed on the page Oct 4, 2026. fda.gov ↗

Related records

Other firms listing semaglutide, tirzepatide, liraglutide and retatrutide

FDA registers on this site

Sources

• FDA NDC directory via openFDA ↗, updated by FDA Oct 2, 2026.
• Application holders: Drugs@FDA, updated by FDA Oct 2, 2026.
• FDA’s National Drug Code Directory page ↗ for the quoted definitions.
• Read by us Oct 4, 2026. Not medical advice; this page describes filings, not products’ safety.